New Zealand markets open in 4 hours 41 minutes
  • NZX 50

    11,316.46
    +49.07 (+0.44%)
     
  • NZD/USD

    0.6460
    +0.0049 (+0.77%)
     
  • ALL ORDS

    7,398.90
    +7.90 (+0.11%)
     
  • OIL

    110.11
    -0.17 (-0.15%)
     
  • GOLD

    1,847.20
    +5.10 (+0.28%)
     

Will Demand for Rapid COVID-19 Tests Help Abbott Laboratories Beat the Market in 2022?

·4-min read
Will Demand for Rapid COVID-19 Tests Help Abbott Laboratories Beat the Market in 2022?

In particular, Abbott Laboratories (NYSE: ABT) makes BinaxNOW kits, which are the most popular rapid coronavirus antigen diagnostic test in the U.S. Are things different this time as a result of the omicron variant wave, or is Abbott on track to disappoint? Coronavirus rapid testing revenue has been all over the place, appearing to ebb and flow based on the public's perceptions about where the pandemic is headed.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting